Powered by Business Wire
Biotechnology Headlines

Harvard Apparatus Regenerative Technology Schedules Release of Second Quarter 2014 Financial Results and Investor Teleconference for August 8th

Conference Call to Occur at 11:00 A.M. ET That Day

HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its second quarter ended June 30, 2014 before market trading hours on Friday, August 8, 2014. A conference call to discuss the company’s second quarter results and the company’s operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.

Investors can access the live conference call by dialing the following phone numbers: toll-free 888-455-2260, or toll/international: 719-325-2484, and referencing the pass code “9685223”.

If you are unable to listen to the live conference call, a replay will be available from approximately 2:00 PM (Eastern Time) on August 8, 2014 through 2:00 PM (Eastern Time) on August 15, 2014 and will be accessible by dialing toll-free 888-203-1112, or toll/international 719-457-0820, and referencing the pass code “9685223”.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Contacts

Harvard Apparatus Regenerative Technology, Inc.:
David Green
President and CEO
dgreen@HARTregen.com
or
Tom McNaughton
CFO
tmcnaughton@HARTregen.com
or
Investor Relations:
Dian Griesel Int’l.
Cheryl Schneider, 212-825-3210
or
Public Relations:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj
212-825-3210